SEARCH

SEARCH BY CITATION

References

  • 1
    Floege J , Feehally J . IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11: 2395403.
  • 2
    Hiki Y , Tanaka A , Kokubo T et al. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol 1998; 9: 57782.
  • 3
    Allen AC , Bailey EM , Brenchley PE et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001; 60: 96973.
  • 4
    Horie A , Hiki Y , Odani H et al. IgA1 molecules produced by tonsillar lymphocytes are under O-glycosylated in IgA nephropathy. Am J Kidney Dis 2003; 42: 48696.
  • 5
    Allen AC , Topham PS , Harper SJ et al. Leucocyte beta 1,3-galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant 1997; 12: 7016.
  • 6
    Ju T , Brewer K , D'Souza A et al. Cloning and expression of human core 1 beta1,3-galactosyltransferase. J Biol Chem 2002; 277: 17886.
  • 7
    Ju T , Cummings RD . A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A 2002; 99: 166138.
  • 8
    Kudo T , Iwai T , Kubota T et al. Molecular cloning and characterization of a novel UDP-Gal:GalNAc(alpha) peptide beta 1,3-galactosyltransferase (C1Gal-T2), an enzyme synthesizing a core 1 structure of O-glycan. J Biol Chem 2002; 277: 4772431.
  • 9
    Lee SM . Prognostic indicators of progressive renal disease in IgA nephropathy: emergence of a new histologic grading system. Am J Kidney Dis 1997; 29: 9538.
  • 10
    Haas M . Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 82942.
  • 11
    Whitworth JA . 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 198392.
  • 12
    Norrback KF , Dahlenborg K , Carlsson R et al. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood 1996; 88: 2229.
  • 13
    Allen AC , Willis FR , Beattie TJ et al. Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 1998; 13: 9304.
  • 14
    Pfaffl MW . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
  • 15
    Hennet T . The galactosyltransferase family. Cell Mol Life Sci 2002; 59: 108195.
  • 16
    Thurnher M , Rusconi S , Berger EG . Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome. J Clin Invest 1993; 91: 210310.
  • 17
    Kokubo T , Hiki Y , Iwase H et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998; 9: 204854.
  • 18
    Roccatello D , Picciotto G , Torchio M et al. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Lab Invest 1993; 69: 71423.
  • 19
    Basset C , Devauchelle V , Durand V et al. Glycosylation of immunoglobulin A influences its receptor binding. Scand J Immunol 1999; 50: 5729.
  • 20
    Moura IC , Centelles MN , Arcos-Fajardo M et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194: 41725.
  • 21
    Tomana M , Matousovic K , Julian BA et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997; 52: 50916.
  • 22
    Tomana M , Julian BA , Waldo FB et al. IgA nephropathy. A disease of incomplete IgA 1 glycosylation? Adv Exp Med Biol 1995; 376: 221.
  • 23
    Kokubo T , Hashizume K , Iwase H et al. Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transplant 2000; 15: 2833.
  • 24
    Nikolova EB , Tomana M , Russell MW . The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA. Immunology 1994; 82: 3217.
  • 25
    Amore A , Cirina P , Conti G et al. Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 2001; 12: 186271.
  • 26
    Gomez-Guerrero C , Gonzalez E , Hernando P et al. Interaction of mesangial cells with IgA and IgG immune complexes: a possible mechanism of glomerular injury in IgA nephropathy. Contrib Nephrol 1993; 104: 12737.
  • 27
    Peruzzi L , Amore A , Cirina P et al. Integrin expression and IgA nephropathy: in vitro modulation by IgA with altered glycosylation and macromolecular IgA. Kidney Int 2000; 58: 233140.
  • 28
    Amore A , Conti G , Cirina P et al. Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis 2000; 36: 124252.